Dr Reddys Laboratories (RDY) Net Income towards Common Stockholders Growth (1y) (2010 - 2021)
Dr Reddys Laboratories (RDY) Net Income towards Common Stockholders Growth (1y) (2010 - 2021) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.92 Bn | 42.96 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.53 Bn | 2.15 Bn | -304.98% |
| 3 | Zoetis | 31.74 Bn | 30.06 Bn | 1.05 Bn | -5.04% |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.87 Bn | 5.10 Bn | -17.29% |
| 5 | United Therapeutics | 22.22 Bn | 19.56 Bn | 683.80 Mn | 7.59% |
| 6 | Viatris | 18.71 Bn | 17.83 Bn | 1.46 Bn | -2,482.61% |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 34.33% |
| 8 | Elanco Animal Health | 11.80 Bn | 11.27 Bn | 798.00 Mn | 390.91% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Alkermes | 8.12 Bn | 7.47 Bn | 397.90 Mn | -99.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -10.07% |
| Mar 31, 2021 | -2.53% |
| Sep 30, 2020 | -35.00% |
| Jun 30, 2020 | -2.61% |
| Mar 31, 2020 | -15.96% |
| Sep 30, 2019 | -214.29% |
| Jun 30, 2019 | 121.74% |
| Mar 31, 2019 | 49.21% |
| Dec 31, 2018 | 43.18% |
| Sep 30, 2018 | 37.25% |
| Dec 31, 2017 | -8.33% |
| Sep 30, 2017 | -40.00% |
| Dec 31, 2016 | -38.46% |
| Sep 30, 2016 | -3.41% |
| Dec 31, 2015 | -6.02% |
| Sep 30, 2015 | -10.20% |
| Dec 31, 2014 | -12.63% |
| Sep 30, 2014 | -2.00% |
| Mar 31, 2014 | 50.82% |
| Dec 31, 2013 | -9.52% |